Biophan and New Scale Announce SQUIGGLE Motor Named to EE Times' Top Ten ''Most Significant'' Products List.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, and New Scale Technologies, Inc., a developer of miniature ceramic motors, have announced that the SQUIGGLE (R) motor was named an "ULTIMATE PRODUCT" in the June 6 issue of EE Times. The SQUIGGLE motor is a linear motor with nanometer precision, made of piezoelectric ceramics and other non-magnetic materials, making it safe and compatible for use with Magnetic Resonance Imaging (MRI) for both implantable and robotic applications.

EE Times is a weekly technical journal read by more than 150,000 design and development engineers and technical managers. It is consistently chosen as the best-read and most preferred publication in the industry.

To create the ULTIMATE PRODUCTS report, the magazine's technical editors selected up to 10 of the most significant products introduced during the quarter, in each of seven categories. They then invited selected readers of EE Times and eeProductCenter to rate these products on "technical significance" and "likelihood of use."

The SQUIGGLE motor was voted # 4 for technical significance in the Interconnects, Packaging and Electromechanical products (IP&E) section of the ULTIMATE PRODUCTS 2.1 report (http://www.eeproductcenter.com/ultimate/2.1)

One EE Times reader commented; "As an engineer in the MRI field, I could see the SQUIGGLE motor becoming an integral part of MRI-compatible devices."

SQUIGGLE motors are available for immediate delivery from New Scale Technologies and from Biophan, New Scale's exclusive distributor of SQUIGGLE motors for medical applications.

About New Scale Technologies

New Scale Technologies, Inc. (www.newscaletech.com) makes miniature ceramic motors that enable our customers to create smaller products. New Scale's patented SQUIGGLE motors are bigger than MEMS devices but smaller than conventional motors. New Scale generates precise movement using ultrasonic vibrations, which makes our piezoelectric motors powerful, precise, simple, and compatible with extreme environments.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.